VANCOUVER, BC / ACCESSWIRE / May 21, 2019 / Theramed Health Corporation (CSE: TMED, OTCQB: EVAHF) (the “Company“) is pleased to announce that effective today it has closed on $505,000 of gross proceeds as a first tranche on a non-brokered private placement of up to one million Canadian dollars for units at $0.10 comprised of one common share and one full warrant exercisable at $0.15 into one common share for a period of three years from the closing. The warrants will be subject to an acceleration clause where in the event the share price of the company’s shares as currently constituted close at $$0.30 or above for 20 consecutive days the company may accelerate the expiration of the warrants to 30 calendar days from the day that notice is given for the exercise of the warrants. There is a finders’ fee for any agents and brokers who would be entitled to receive a commission of 6% cash commission of the gross proceeds and 6% commission in broker warrants.

Corporate Update

The Company is continuing work on developing products, research, and health technologies for commercialization of CBD based protocols and product development for a CBD Health System As a result of this focus the company has or is planning to do the following:

Cancellation of previously announced Letter of Intent with West Coast Medical Solutions;

Holding a Special and Annual General Meeting to conduct a Plan of Arrangement to propose the spin-out of:

Artillery Labs LOI and

The excipient research and development joint venture

Entered into an agreement to engage Link Media, LLC for US $180,000 in digital communications and media services for building the rebranded profile of the company.

Theramed Health Corporation – is a technology company focused in the healthcare and life sciences sector to develop a personalized healthcare system. The company has recently been focused on utilizing CBD derived from Hemp as a core component. The company through its subsidiaries has assets and technologies involved in extracting and purifying CBD extracts, creating formulations through its key scientists, and with its medical device technology monitoring capabilities. Theramed’s unique combination of technologies may allow it to be the first to be able to offer a complete quality assured vertically integrated “CBD Health System” for monitoring, dosing, and recording the effects of CBD on your cardiovascular system.

Disclaimers

This news release contains forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators and on the OTC Markets website which is posted on www.sedar.com, http://thecse.com/en/listings/technology/Theramed-Health-Corporation, and http://www.otcmarkets.com/stock/EVAHF/filings. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), or any other regulatory authority accepts responsibility for the adequacy or accuracy of this release. The Company does not undertake to update this news release unless required by applicable law.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law and may not be offered or sold in the “United States”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.